IGF-1 LR3 Price Comparison — Compare 21 Vendors

View full research →
Muscle / IGF researchSafety Rating 3/10

Price Comparison

Compare vendors · per 1mg

21 vendors competing

VendorPrice$ / mgUpdated
SomaChems7/10$47.99$59.99−20% · code PEPTIDEPRICES$47.99May 14, 2026Buy →
Amino Club10/10$55.99$69.99−20% · code PEPTIDEPRICES$55.99May 14, 2026Buy →
Evo Labs Research8/10$59.49$69.99−15% · code JACKR3CCC$59.49Jun 22, 2026Buy →
LA Peptides6/10$59.99$59.99May 14, 2026Buy →
Woosh Labs8/10$62.99$69.99−10% · code peptideprices$62.99Jun 24, 2026Buy →
Pinnacle Peptide Labs8/10$67.99$79.99−15% · code PEPTIDEPRICES15$67.99Apr 23, 2026Buy →

Research details

IGF-1 LR3 — research data

Research-literature reference data, NOT patient instructions. Not for human use. Consult a licensed clinician for any human application.

Research dose rangeLimited human clinical data; research protocols 20–50 mcg/day SCsource ↗
AdministrationSubcutaneous injection
Half-life~20–30 hours
Safety3/10 · Not FDA-approved (never tested in humans)
NCAA D1Banned

Overview

About IGF-1 LR3

Mechanism of action

Analogue of IGF-1 with arginine substitution at position 3 and N-terminal extension; binds IGF-1 receptors; promotes muscle cell hyperplasia and hypertrophy; inhibits apoptosis; enhances nutrient uptake.

Safety profile

Hypoglycemia (most significant risk), jaw/organ growth with high doses, insulin resistance, acromegaly risk, water retention, potential cancer promotion. · Documented animal DEATHS from prolonged (20–30h) hypoglycemia; severe acute hypoglycemia risk; cancer-proliferation concern (IGF-1 epidemiologically linked to several cancers); zero human trials; species-paradoxical responses. WADA-banned.

Storage

Stability & handling

❄️Lyophilized (powder)−20°Cstable long-term
💉Reconstituted2–8°Cwithin 30 days
📈

Price tracking starts now.

Set an alert to get notified when this peptide drops.

Safety & Interactions

Contraindications & Drug Interactions

Research use only — not medical advice. Consult a licensed physician before using any peptide. Sources are cited where available.

⚠ CriticalContraindication

Active malignancy — IGF-1 is a potent growth factor with documented tumor-promoting activity in preclinical models.

⚠ CriticalContraindication

Severe hypoglycemia history or type 1 diabetes — IGF-1 causes significant hypoglycemia.

⚠ CriticalContraindication

Hypersensitivity to IGF-1 or benzyl alcohol.

Sources: FDA

Related pages

More on IGF-1 LR3

Stack & Compare

Frequently Researched Together

Research

Studies & key findings

  • Long R3 modification (Arg substitution at position 3 + 13-aa N-terminal extension) reduces IGF-binding protein (IGFBP) affinity by >95%, extending half-life from ~10 min to 20–30 hours.
  • Demonstrated superior anabolic potency vs native IGF-1 in dexamethasone-treated catabolic rat models, supporting use in muscle-wasting and recovery contexts.

5 peer-reviewed sources cited — clinical, preclinical, and regulatory.

Read full research →
Failed to fetch